Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer 2014 Apr;61(4):756-9
Date
10/12/2013Pubmed ID
24115645DOI
10.1002/pbc.24785Scopus ID
2-s2.0-84893463503 (requires institutional sign-in at Scopus site) 28 CitationsAbstract
As most active chemotherapy agents against Wilms tumor are incorporated into upfront therapy, particularly for those patients with high risk for recurrence, novel regimens are needed to treat children with relapsed Wilms tumor. We describe four consecutive patients with multiply relapsed Wilms tumor who were treated with a combination of vincristine, irinotecan, temozolomide, and bevacizumab. Two had a complete response, and two had a partial response to treatment. Hematological toxicity and diarrhea were the main side effects. This regimen has activity in patients with multiply relapsed Wilms tumor without excessive toxicity, and should be evaluated further in this setting.
Author List
Venkatramani R, Malogolowkin MH, Mascarenhas LMESH terms used to index this publication - Major topics in bold
AdolescentAntibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Camptothecin
Child
Dacarbazine
Female
Humans
Kidney Neoplasms
Male
Neoplasm Recurrence, Local
Neoplasm Staging
Prognosis
Vincristine
Wilms Tumor
